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Abstract
Background: The leading cause of death for patients suffering from diabetes is macrovascular disease. Endothelial
dysfunction is often observed in type 2 diabetic patients and it is considered to be an important early event in the
pathogenesis of atherogenesis and cardiovascular disease. Many drugs are clinically applied to treat diabetic
patients. However, little is known whether these agents directly interfere with endothelial cell proliferation and
apoptosis. This study therefore aimed to investigate how anti-diabetic and cardioprotective agents affect human
coronary artery endothelial cells (HCAECs).
Methods: The effect of anti-diabetic and cardioprotective agents on HCAEC viability, proliferation and apoptosis
was studied. Viability was assessed using Trypan blue exclusion; proliferation in 5 mM and 11 mM of glucose was
analyzed using [
3H]thymidine incorporation. Lipoapoptosis of the cells was investigated by determining caspase-3
activity and the subsequent DNA fragmentation after incubation with the free fatty acid palmitate, mimicking
diabetic lipotoxicity.
Results: Our data show that insulin, metformin, BLX-1002, and rosuvastatin improved HCAEC viability and they
could also significantly increase cell proliferation in low glucose. The proliferative effect of insulin and BLX-1002
was also evident at 11 mM of glucose. In addition, insulin, metformin, BLX-1002, pioglitazone, and candesartan
significantly decreased the caspase-3 activity and the subsequent DNA fragmentation evoked by palmitate,
suggesting a protective effect of the drugs against lipoapoptosis.
Conclusion: Our results suggest that the anti-diabetic and cardioprotective agents mentioned above have direct
and beneficial effects on endothelial cell viability, regeneration and apoptosis. This may add yet another valuable
property to their therapeutic effect, increasing their clinical utility in type 2 diabetic patients in whom endothelial
dysfunction is a prominent feature that adversely affect their survival.
Keywords: Diabetes, Endothelium, Coronary artery disease, Insulin, Statin, Metformin, Lipids, AT1-receptor antago-
nist, Peroxisome proliferator-activated receptor gamma agonist
Background
The prevalence of diabetes among adults worldwide was
estimated in 2010 to 6.4%, thus affecting 285 million
adults. This figure is predicted to rise to 7.7%, in num-
bers 439 million, by 2030 [1]. In patients with diabetes,
the major cause of death is macrovascular disease [2,3],
and in individuals with type 2 diabetes, the main etiology
for up to 75% of the mortality is atherosclerotic
cardiovascular disease [4]. In contrast to microangiopa-
thies (e.g. nephropathy and retinopathy), where the causal
relation to hyperglycemia is well supported, the link
between hyperglycemia and macroangiopathy is uncer-
tain, at least in terms of the possibility of reducing
macrovascular morbidity solely by reducing hyperglyce-
mia. Most patients with diabetes are consequently being
treated with one or more antidiabetic drugs, a lipid-
lowering statin and an ACE inhibitor or angiotensin
receptor antagonist for hypertension and/or albuminuria. * Correspondence: qmnzhang@yahoo.com; ake.sjoholm@sodersjukhuset.se
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that line the lumen of blood vessels and form a physical
barrier between circulating blood and the vascular smooth
muscle cells. The endothelium plays a very important role
in maintenance of vascular integrity by protecting the
vessels from activation of clotting and proinflammatory
factors. It also participates in the regulation of blood flow
and blood pressure [5]. Loss of physiological features of
the endothelium, such as its preference to support vasodi-
latation, fibrinolysis and antiaggregation, is referred to as
endothelial dysfunction [6], which has been observed in
diabetes (type 1 and type 2), in obesity and in patients
with insulin resistance. In fact, the extent of endothelium-
dependent vasodilatation correlates in obese and insulin
resistant subjects with their individual insulin sensitivity
[7,8]. Endothelial dysfunction has thus emerged as an
important early target for preventing atherosclerosis and
cardiovascular disease [9].
Hyperglycemia and hyperlipidemia are important factors
in the development of endothelial dysfunction. Free fatty
acids (FFAs), formed during lipolysis from triglycerides,
and hyperglycemia are known to impair the endothelial-
dependent vasodilatation [10,11]. Increased plasma levels
of FFAs and glucose are characteristic features in patients
with type-2 diabetes. Both factors are known induce apop-
tosis of endothelial cells and endothelial cell death is
believed to be involved in, and contribute to, endothelial
dysfunction and atherosclerosis [12-14].
Current anti-diabetes drugs are mainly aimed to correct
hyperglycemia by promoting pancreatic b-cell insulin
secretion, increasing insulin sensitivity, or reducing intest-
inal glucose uptake and hepatic gluconeogenesis. Apart
from insulin, glimepiride, a third generation sulfonylurea
[15], pioglitazone, a peroxisome proliferator-activated
receptor gamma (PPAR-g) agonist, and a member of the
thiazolidinedione family (TZD) [16], and metformin, a
biguanide, are used for treatment of type 2 diabetes [9].
Candesartan, an angiotensin II receptor antagonist, and
rosuvastatin, a competitive inhibitor of the enzyme HMG-
CoA reductase, are used for management of hypertension
and hyperlipidemia, respectively [17,18]. In addition, we
have also studied BLX-1002, a novel thiazolidinedione
with no structural resemblance to other TZDs [19], which
does not appear to affect PPARs. There is evidence that
BLX-1002 can improve hyperglycemia in diabetic animal
models without the body weight gain typically associated
with PPARg-mediated adipocyte differentiation [19,20].
N o tm u c hi sk n o w na b o u tB L X - 1 0 0 2 ,b u ti th a sb e e n
shown to potentiate insulin secretion from islets in a phos-
phatidylinositol 3-kinase (PI3K)-dependent manner. BLX-
1002 also activates AMP-activated protein kinase (AMPK)
[20] perhaps through its ability to inhibit the mitochon-
drial complex 1 [19,21].
Compared to studies on the actions of the above drugs
on glycemia, little has been done regarding their direct
actions on proliferation and apoptosis of human coronary
artery endothelial cells (HCAECs). Understanding the
effects of these agents is important as endothelial growth
and apoptosis are involved in endothelial repair and func-
tion. Disruption of the intimal layer subjects the arterial
wall to greater risk for macrovascular disease [14], the
most common etiology for morbidity and mortality in dia-
betic patients [15]. Therefore, the aim of our study was to
investigate the effects of drugs used in treatment of dia-
betic patients on proliferation and lipotoxicity-induced
apoptosis in HCAECs.
Methods
Materials
Clonetics™ HCAECs, culture medium EGM-2 MV and
cell culture supplements were purchased from Lonza
(Basel, Switzerland). Insulin lispro was from Eli Lilly and
Company (Indianapolis, IN), C-peptide was generously
provided by Prof. John Wahren (Creative Peptides, Inc.,
Stockholm, Sweden), and pioglitazone was graciously
donated by Takeda Pharmaceuticals North America, Inc.
(Lincolnshire, IL). Metformin, glimepiride, sodium palmi-
tate, and bovine serum albumin (BSA) (fatty acid free)
were purchased from Sigma-Aldrich (St. Louis, MO).
Rosuvastatin and candesartan were kindly given by Astra-
Zeneca (London, United Kingdom). BLX-1002 was
graciously donated by Bexel Pharmaceuticals, Inc. (Union
City, CA). [
3H]thymidine was bought from Amersham
Biosciences (Piscataway, NJ), EnzChek
® caspase-3 activity
assay kits from Molecular Probes
®, Life Technologies
(Carlsbad, CA), DNA fragmentation ELISA kits from
Roche Diagnostics (Mannheim, Germany), and DC™
Protein Assay from BioRad Laboratories (Hercules, CA).
Cell culture
HCAECs, isolated from normal human coronary arteries
[22], were grown in EGM-2 MV medium supplemented
with hydrocortisone, human epidermal growth factor
(hEGF), 5% fetal bovine serum (FBS), vascular endothelial
growth factor (VEGF), human fibroblast growth factor
(hFGF)-B, R3-insulin-like growth factor (IGF)-1, ascorbic
acid and gentamicin/amphotericin-B at 37°C in a humidi-
fied (5% CO
2, 95% air) atmosphere as recommended by
the supplier. Passage 5-12 were used in the study for eva-
luation of cell viability, [
3H]thymidine incorporation
rates, DNA fragmentation ELISA and caspase-3 activity
assays. Confluent cultures were detached by trypsination
and seeded onto tissue culture dishes and grown until
80-90% confluence. Cells were incubated overnight in
serum-deficient EGM medium containing 0.5% FBS and
2 mM L-glutamine prior to 24 or 48 h incubation in the
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cells was approved by the Research Ethics Committee,
Stockholm South, Dnr: 232/03.
Cell viability
Cells were incubated with serum deficient medium, in
t h ep r e s e n c eo ra b s e n c eo ft h ed r u g sf o r4 8h .C e l l
number was manually counted in a hemocytometer and
cell viability assessed by Trypan blue exclusion.
[
3H]thymidine incorporation
Rates of [
3H]thymidine incorporation into DNA were ana-
lyzed as previously described [22,23] and used as a measure
of DNA synthesis. In brief, cells were cultured until 80%
confluence. After serum starvation over night, cells were
incubated in the presence of the agents or vehicle for 24 h
at 5 mM or 11 mM glucose to simulate a normoglycemic
and hyperglycemic milieu, respectively. Cells were pulsed
with [
3H]thymidine (1 μCi/ml) 8 h prior to the end of the
incubation. Cells were then collected and homogenized
through ultrasonication. The labeled cells were precipitated
in ice-cold 10% trichloroacetic acid (TCA). The precipitate
was washed with 10% TCA and [
3H]thymidine incorpora-
tion into DNA was measured using a microplate scintilla-
tion and luminescence counter (Wallac MicroBeta
® Trilux,
PerkinElmer) [24]. The protein concentration of the sam-
ples was measured using DC™ Protein Assay (Bio-Rad
Laboratories).
Caspase-3 activity
Cells were cultured to 90% confluence. After incubation
in serum deficient medium overnight, cells were pre-
treated for 1 hour with the drugs or solvents, after which
the incubation was continued for 24 h in the presence of
0.125 mM palmitate/0.25% BSA or vehicle [13]. Caspase-
3 activity, a measure of apoptosis, was evaluated using
the EnzChek
® Caspase-3 Assay Kit (Molecular Probes
®,
Life Technologies) according the manufacturer’s instruc-
tions. The assay is based on the 7-amino-4-methylcou-
marin-derived substrate Z-DEVD-AMC, which yields a
fluorescent product (excitation/emission ~342/441 nm)
upon proteolytic cleavage by active caspase-3. All results
were normalized to the protein concentration of the cor-
responding sample using DC™ Protein Assay (Bio-Rad
Laboratories).
DNA fragmentation
Cells were cultured to 90% confluence and treated in the
same way as described for the caspase-3 activity assay. Cell
apoptosis was analyzed using the Cell Death Detection Kit
plus (Roche Diagnostics) according the manufacturer’s
instructions. The Cell Death Detection Kit measures cyto-
plasmic DNA-histone nucleosome complexes generated
during apoptotic DNA fragmentation. Samples were
measured at 405 nm and corrected for background signals
caused by irregular microtiter plates or light scattering due
to solid particles in the solution at the reference wavelength
of 492 nm. Separate wells were seeded for protein concen-
tration measurements using DC™ Protein Assay (Bio-Rad
Laboratories). Absorbance data was normalized to the pro-
tein concentration of the corresponding treatment.
Statistical analysis
Results are expressed as mean ± SEM. Statistical analysis
was performed using Student’s t-test or ANOVA, as appro-
priate. P < 0.05 was considered statistically significant.
Results
Agents that were used in this study were the following:
insulin lispro (100 pM, 1 nM), C-peptide (1 nM), pioglita-
zone (2.5 μM), metformin (500 μM), glimepiride (1 μM),
rosuvastatin (10 nM), candesartan (100 nM) and BLX-
1002 (1 μM). Of the compounds tested, we were unable to
detect any effect of C-peptide on either proliferation or
apoptosis of the cells. All agents have been tested in all
conditions, but only compounds that were able to exert
significant effects are displayed in the graphs.
Cell viability of HCAECs is increased by the agents
As shown in Figure 1, among the agents tested, BLX-1002
and insulin (the latter at both 100 pM and 1 nM)
increased cell viability. Exposure of the cells to metformin
also resulted in a slight, but statistically significant,
increase in cell viability. Under the same conditions, cell
viability was also augmented by rosuvastatin, pioglitazone,
candesartan and glimepiride.
Insulin, BLX-1002, metformin and rosuvastatin stimulate
proliferation of HCAECs at normal glucose concentration
Since the increased viability noted above (Figure 1) could
be explained by increased proliferation, decreased apopto-
sis, or a combination thereof, we investigated if the drugs
exert any effect on HCAECs’ DNA synthesis. Rates of [
3H]
thymidine incorporation were analyzed after a 24 hour
exposure to the agents at 5 mM glucose. The mitogenic
effect of the compounds was also verified by measuring
protein concentrations of the samples to reflect an
increase in cell number. As shown in Figure 2, insulin,
BLX-1002, metformin and rosuvastatin increased both
DNA synthesis and protein concentration significantly.
Insulin and BLX-1002 stimulate proliferation of HCAECs at
high glucose
Since insulin, BLX-1002, metformin and rosuvastatin
were able to increase the proliferation of HCAECs in 5
mM glucose (Figure 2), we further investigated whether
they had any effect on cell proliferation at high glucose.
HCAECs were therefore exposed to 11 mM of glucose,
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of the agents. Similar to the effect observed at 5 mM glu-
cose, insulin and BLX-1002 were both able to increase
DNA synthesis and protein concentration (Figure 3). In
contrast to their effects at 5 mM glucose, metformin and
rosuvastatin did not exert any effect on cell proliferation
under these conditions (data not shown).
Insulin, BLX-1002, metformin, pioglitazone and
candesartan suppress lipoapoptosis in HCAECs
Plasma FFA levels are increased in type-2 diabetic
patients and the FFA palmitate is known to induce
apoptosis of endothelial cells [13]. We therefore evalu-
ated how the agents affected the activity of cleaved cas-
pase-3, a crucial mediator of apoptosis [25], in HCAECs
after 24 hour exposure to 0.125 mM palmitate. As
shown in Figure 4, palmitate significantly increased cas-
pase-3 activity, thus confirming its pro-apoptotic effect,
in HCAECs. Insulin, BLX-1002, metformin, pioglitazone
and candesartan significantly decreased the palmitate-
induced caspase-3 activation, suggesting a protective
effect of the drugs against lipotoxicity in HCAECs. Gli-
mepiride significantly decreased basal caspase-3 activity
with ~20% (data not shown), which might explain why
an increased viability of the cells in the presence of gli-
mepiride is noted (Figure 1).
To corroborate the anti-apoptotic effect of the agents
above, we investigated their influence on palmitate-
induced DNA fragmentation by analyzing cytoplasmic
DNA-histone nucleosome complexes generated during
apoptosis. Palmitate alone gave rise to a markedly
increased apoptosis of the HCAECs (Figure 5). Co-incuba-
tion with insulin, BLX-1002, metformin, pioglitazone or
candesartan significantly countered the palmitate-induced
apoptosis, thus confirming the protective effect of these
agents against lipoapoptosis in HCAECs.
Discussion
Our major findings in this study are that insulin, BLX-
1002, metformin and rosuvastatin exert positive effects on
regeneration and viability of HCAECs. Insulin, BLX-1002,
metformin, pioglitazone and candesartan also conferred
protection of HCAECs against lipotoxicity.
Proliferation of HCAECs is induced in normal and high
glucose levels
By studying how the agents affect DNA synthesis, through
analysis of the incorporation of radiolabeled thymidine
into DNA, we found that insulin, BLX-1002, metformin
and rosuvastatin increased the HCAECs’ DNA synthesis
and subsequently the protein concentration in 5 mM glu-
cose. Taken together, this suggests that the above agents
stimulate HCAEC proliferation at normal glucose concen-
trations. The mitogenic effect seen with the compounds
probably explain, at least in part, the increased viability.
Kageyama et al. recently showed that when HCAECs
were exposed to glucose concentrations ranging from
5.6-16.7 mM apoptosis was dose dependently increased.
This was also coupled to an increased expression of the
death receptors TNF-R1 and Fas [26]. High glucose is
also known to cause oxidative stress through generation
of reactive oxygen species (ROS) in HCAECs as recently
shown by Serizawa et al. [27]. This might be due to on
uncoupling of endothelial nitric oxide synthase (eNOS)
and increased activity of the NADPH oxidase [27].
Increased levels of glucose might also cause proliferative
Figure 1 Insulin, metformin, BLX-1002, rosuvastatin, pioglitazone,
candesartan and glimepiride increase HCAEC viability. Cells were
incubated for 48 h in medium supplemented with 0.5% FBS in the
presence or absence of insulin lispro (100 pM and 1 nM), metformin
(500 μM), BLX-1002 (1 μM), rosuvastatin (10 nM), pioglitazone (2.5 μM),
candesartan (100 nM) and glimepiride (1 μM). Viability was assessed
with Trypan blue exclusion. * denotes P < 0.05, ** denotes P < 0.01,
*** denotes P < 0.001 for chance differences compared to controls by
Student’s t-test.
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to contribute to premature development of atherosclero-
sis [30]. We therefore wanted to test if the above agents
also stimulate HCAEC proliferation at 11 mM glucose,
simulating a diabetic milieu. We found that insulin and
BLX-1002 were the only two agents that could promote
cell proliferation in high glucose. The mitogenic effect
of the agents in HCAECs may prove beneficial in
dampening or delaying coronary atherosclerosis, by
rapidly covering a vascular wall lesion with endothelium
and thus protecting it from further atherothrombotic
events. It may also be favorable for diabetic patients with
coronary artery disease undergoing percutaneous coron-
ary revascularization and treated with drug-eluting stents.
It is believed that delayed re-endothelization is a major
underlying problem for late-stent thrombosis [31] and
Figure 2 Insulin, BLX-1002, metformin and rosuvastatin stimulate HCAEC proliferation at normal glucose concentration.I no r d e rt o
study the effects of agents on proliferation of HCAECs, cells were incubated at 5 mM of glucose in medium supplemented with 0.5% FBS for 24
h in the presence or absence of insulin lispro (100 pM), metformin (500 μM), BLX-1002 (1 μM), rosuvastatin (10 nM). Eight hours prior to the end
of the incubation, cells were pulsed with [
3H]thymidine. Cells were then harvested and [
3H]thymidine incorporation into DNA was measured
using a microplate scintillation & luminescence counter, and the protein concentration of the samples was measured using DC™ Protein Assay.
* denotes P < 0.05, ** denotes P < 0.01, *** denotes P < 0.001 for chance differences vs. controls by Student’s t-test.
Figure 3 Insulin and BLX-1002 stimulate HCAEC proliferation in high glucose. HCAECs were incubated at 11 mM of glucose in medium
supplemented with 0.5% FBS for 24 h in the presence or absence of insulin lispro (100 pM) or BLX-1002 (1 μM). Eight hours prior to the end of
the incubation, cells were pulsed with [
3H]thymidine. Cells were then harvested and [
3H]thymidine incorporation into DNA was measured using
a microplate scintillation & luminescence counter and the protein concentration of the samples was measured using DC™ Protein Assay. *
denotes P < 0.05, ** denotes P < 0.01, *** denotes P < 0.001 for a chance difference vs. control by Student’s t-test.
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restenosis, which is the major limitation with this treat-
ment [32].
The underlying mechanisms involved in the agents’
proliferative effects were not investigated in this scanning
study, but will be subject to future work. However, the
effects are consistent with previous findings insofar that
insulin at supraphysiological concentrations increases
[
3H]thymidine incorporation in endothelial cells [33].
Insulin and rosuvastatin have also been shown to activate
the PI3K/Akt pathway, a pathway that is well known to
be involved in cell survival and proliferation
[18,22,34-36]. BLX-1002 is a novel compound of the
TZD family, but with no apparent PPAR affinity. We
have previously demonstrated that it can signal through
PI3K and is able to activate AMPK in insulin-secreting
cells [20]. Also, metformin is a known activator of
AMPK, and AMPK activates eNOS [37], an important
factor for proliferation of HCAECs [22].
HCAECs are protected from lipoapotosis
Plasma levels of FFAs are typically elevated in diabetic
patients and FFAs are known to impair endothelial-
dependent vasodilatation [11,38]. FFAs are also known to
cause apoptosis of endothelial cells [13,38]. Apoptosis of
HCAECs might disrupt the endothelial monolayer of the
coronary artery wall and might contribute to a proinflam-
matory environment that could lead to premature
Figure 4 Insulin, metformin, BLX-1002, pioglitazone and candesartan protect HCAECs against palmitate-induced caspase-3 activation.
Palmitate-induced caspase-3 activity, a measure of apoptosis, was evaluated using the EnzChek
® Caspase-3 Assay Kit. HCAECs were incubated in
medium containing 5 mM glucose, supplemented with 0.5% FBS, with or without insulin lispro (1 nM), BLX-1002 (1 μM), metformin (500 μM),
pioglitazone (2.5 μM), candesartan (100 nM) in the presence of 0.125 mM palmitate or vehicle (ethanol and BSA) for 24 h. * denotes P < 0.05 for
a chance difference vs. controls by ANOVA. # denotes P < 0.05 for a chance difference vs. palmitate by ANOVA.
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osclerosis [13,38]. We therefore addressed whether the
above agents protect HCAECs against apoptotic cell
death caused by the fatty acid palmitate, simulating dia-
betic hyperlipidemia. Our results are commensurate with
other reports in the literature. Insulin has previously
been shown to protect human umbilical vein endothelial
cells (HUVECs) from palmitate-induced apoptosis
through activation of the PI3K/Akt pathway [38]. BLX-
1002, whose functions are essentially unknown, has been
shown to promote insulin secretion in pancreatic b-cells,
an effect that involves PI3K and AMPK activation [20].
Since both PI3K and AMPK convey anti-apoptotic sig-
nals in other cell types [38-41], these pathways may also
be operative in HCAECs. This also holds true for
metformin, which can activate AMPK and indeed, speci-
fic activation of AMPK has been shown to protect bovine
aortic endothelial cells from palmitate-induced apoptosis
[41]. The anti-apoptotic effect of pioglitazone observed in
the present study is consistent with findings in both
HUVECs and endothelial progenitor cells (EPCs) [42,43].
Although the mechanisms behind such effect remain
unclear and will be addressed in forthcoming studies, pal-
mitate induces ROS in endothelial cells [41] and pioglita-
zone has been shown to decrease ROS formation in such
cells [44]. This might contribute to its anti-apoptotic effect
since oxidative stress is known to induce cell death
[14,44]. Pioglitazone has also been shown to protect
HCAECs from tumor necrosis factor alpha induced cas-
pase-3 activity and apoptosis [45]. To the best of our
Figure 5 Insulin, metformin, BLX-1002, pioglitazone and candesartan protect HCAECs against palmitate-induced DNA fragmentation.
To further corroborate the protective effects of the agents against lipotoxicity-induced apoptosis, DNA fragmentation was evaluated using the
Cell Death Detection kit ELISA
plus. Cells were exposed for 24 h to 0.125 mM palmitate or vehicle at 5 mM glucose with or without insulin lispro
(1 nM), BLX-1002 (1 μM), metformin (500 μM), pioglitazone (2.5 μM), candesartan (100 nM). * denotes P < 0.05 for a chance difference vs controls
by ANOVA, # denotes P < 0.05 for a chance difference vs palmitate by ANOVA.
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of candesartan on lipoapoptosis of endothelial cells. But,
in support to our findings, candesartan has been shown to
protect from hypoxia-induced endothelial cell apoptosis
through pathways involving increased eNOS expression
and decreased caspase-3 activity [17]. Candesartan’sa b i l i t y
to modulate the caspase-3 activity might also contribute to
its positive effects on cell viability.
Conclusions
Abnormal proliferation and apoptosis of endothelial cells
are involved in endothelial dysfunction, damage and
repair. It thus contributes to the premature development
of atherosclerosis and vascular complications in diabetes,
making it important to understand the influence of cur-
rently applied anti-diabetic and cardioprotective agents on
endothelial function. Our results suggest that drugs such
as insulin, metformin, rosuvastatin, pioglitazone and can-
desartan that are oftentimes used in the clinical manage-
ment of diabetic patients have direct and beneficial effects
human coronary artery endothelial cells by promoting
their proliferation and conferring protection against lipo-
toxicity. These findings may add yet another valuable
property to their therapeutic effects, increasing their clini-
cal utility in type 2 diabetic patients in whom endothelial
dysfunction is a prominent feature that adversely affect
their survival.
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